Výsledky vyhledávání

Akademický článek

Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study

Autor: John Stewart, Marcus Hompesch, Jahoon Kang, OakPil Han, Michael E Trautmann, Christopher H Sorli, Ike Ogbaa, Linda Morrow

Publikováno v: BMJ Open Diabetes Research & Care, Vol 9, Iss 1 (2021)

Introduction To evaluate the effects of efpeglenatide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA), on gastric emptying, glucose metabolism, and islet beta-cell function versus liraglutide and placebo in people with type 2 diabe

Externí odkaz: https://doaj.org/article/0f97f81f7a354a72815a206a028b3d29

Zobrazit plný text záznamu

Efficacy and safety of once‐monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo‐controlled, 16‐week randomized dose‐finding study

Autor: Michael Derwahl, Kun-Ho Yoon, Michael E. Trautmann, Stefano Del Prato, Jahoon Kang, Christopher H. Sorli, John Stewart, Alfonso Soto

Publikováno v: Diabetes, Obesity & Metabolism

Aims To determine the optimal dose(s) of once‐monthly administration of efpeglenatide, a long‐acting glucagon‐like peptide‐1 receptor agonist (GLP‐1RA), in patients with type 2 diabetes (T2D) inadequately controlled on metformin. Materials

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3eb9105976927a75f7594a5de9d6dab2
https://doi.org/10.1111/dom.14020

Zobrazit plný text záznamu

Pharmacokinetic and dose‐finding studies on efpeglenatide in patients with type 2 diabetes

Autor: Se Chang Kwon, Michael E. Trautmann, Christopher H. Sorli, Marcus Hompesch, John Stewart, Kun-Ho Yoon, Jahoon Kang

Publikováno v: Diabetes, Obesity & Metabolism

Aim To assess the efficacy, safety and pharmacokinetic/pharmacodynamic properties of efpeglenatide, a long‐acting glucagon‐like peptide‐1 receptor agonist, in patients with type 2 diabetes (T2D). Research design and methods Two randomized, doub

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bdf9e99940128c5013473c7e3c8d900
http://europepmc.org/articles/PMC7383501

Zobrazit plný text záznamu

Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study

Autor: Jahoon Kang, Oakpil Han, John Stewart, Michael E. Trautmann, Ike Ogbaa, Marcus Hompesch, Linda Morrow, Christopher H. Sorli

Publikováno v: BMJ Open Diabetes Research & Care, Vol 9, Iss 1 (2021)
BMJ Open Diabetes Research & Care

IntroductionTo evaluate the effects of efpeglenatide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA), on gastric emptying, glucose metabolism, and islet beta-cell function versus liraglutide and placebo in people with type 2 diabet

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1554064ea8a044cb1f80df514230bd2c
https://drc.bmj.com/content/9/1/e002208.full

Zobrazit plný text záznamu

Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study

Autor: Richard E. Pratley, Stephan Jacob, Jahoon Kang, John Stewart, Kun-Ho Yoon, Michael E. Trautmann, Christopher H. Sorli, Marcus Hompesch, Oakpil Han

Publikováno v: Diabetes, Obesity & Metabolism

Aim To evaluate the safety of efpeglenatide, a long‐acting glucagon‐like peptide‐1 receptor agonist (GLP‐1RA), and its effects on body weight management in adults without diabetes. Materials and methods In this phase II, randomized, placebo�

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a73c2ed37a3e94c46b6337883b2336a
https://doi.org/10.1111/dom.13824

Zobrazit plný text záznamu

A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial

Autor: Hye Sook Han, Jung Yong Kim, Jee Hyun Kim, Seock-Ah Im, Young-Hyuck Im, Jin Seok Ahn, Joohyuk Sohn, Keun Seok Lee, Kyung Hun Lee, Tae Yong Kim, Yeon Hee Park, Ki Hyeong Lee, Jin-Hee Ahn, Se Hyun Kim, In Hae Park, Jahoon Kang, Sung-Bae Kim, Gun Min Kim, Kyung Hae Jung

Publikováno v: International Journal of Cancer. 143:3240-3247

Although the introduction of human epidermal growth factor receptor (HER)2-directed therapy including trastuzumab, pertuzumab, lapatinib and trastuzumab emtansine (T-DM1) in the treatment of HER2-positive metastatic breast cancers (mBCs) favorably ch

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::def9c57d379731ecc2f1014089d308b5
https://doi.org/10.1002/ijc.31651

Zobrazit plný text záznamu

982-P: A Double-Blinded, Placebo Controlled, Single Ascending Dose Study for Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics after Subcutaneous Administration of Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in Healthy Obese Subjects

Autor: Jahoon Kang, Kahee Eun, Jae Duk Choi, Seungjae Baek, Marcus Hompesch, Se Chang Kwon, Youngmin Kim, Linda Morrow

Publikováno v: Diabetes. 68

HM15211 is a novel long-acting GLP-1/GIP/Glucagon triple-receptor co-agonist with extended half-life through reduced renal clearance and through FcRn mediated vascular endothelial recycling. HM15211 has shown therapeutic potential in animal models of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::324c929d40108a5f6fe14473e26b6460
https://doi.org/10.2337/db19-982-p

Zobrazit plný text záznamu

1023-P: Do Baseline Characteristics Impact Efficacy of Efpeglenatide QW in Uncontrolled Type 2 Diabetes?

Autor: George E. Dailey, Christopher H. Sorli, In Young Choi, Ulrich Wendisch, Jahoon Kang, Marcus Hompesch, John A. Stewart, Cristobal Morales, Michael E. Trautmann, Ike Ogbaa, Kun-Ho Yoon, Julio Rosenstock

Publikováno v: Diabetes. 68

Once-weekly (QW), subcutaneous efpeglenatide (EFPEG) is a long-acting GLP-1 RA for T2D management. In EXCEED 203 (NCT02057172), EFPEG QW significantly reduced HbA1c vs. placebo (PBO) for early T2D (naïve/metformin monotherapy). This post hoc subanal

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7d4aecd83bfcfb614d9479c915390508
https://doi.org/10.2337/db19-1023-p

Zobrazit plný text záznamu

1001-P: Effects of Efpeglenatide on Body Weight, BMI, and Waist Circumference in Patients With Obesity Without Diabetes Stratified by Baseline Characteristics: A Subanalysis of BALANCE 205

Autor: John A. Stewart, Stephan Jacob, Ike Ogbaa, Michael E. Trautmann, Richard E. Pratley, Kun-Ho Yoon, Christopher H. Sorli, Jahoon Kang, Oakpil Han, Marcus Hompesch

Publikováno v: Diabetes. 68

Once-weekly (QW) subcutaneous efpeglenatide (efpeg) is a long-acting GLP-1 RA being developed to improve glycemic control in patients with T2D. In the BALANCE 205 study (NCT02075281) in patients with obesity (median BMI 34.9 [28.1−57.7] kg/m2) with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bc6691877d13da5216f909b2b46c2ee2
https://doi.org/10.2337/db19-1001-p

Zobrazit plný text záznamu

1014-P: Relationship between Glycemic Control and Weight Loss with Once-Weekly Efpeglenatide in Uncontrolled Type 2 Diabetes: A Subanalysis of EXCEED 203

Autor: Julio Rosenstock, Christopher H. Sorli, In Young Choi, Marcus Hompesch, Kun-Ho Yoon, John A. Stewart, Cristobal Morales, Ike Ogbaa, Michael E. Trautmann, Ulrich Wendisch, Jahoon Kang, George E. Dailey

Publikováno v: Diabetes. 68

Efpeglenatide (EFPEG) is a long-acting GLP-1 RA, administered by once-weekly (QW) subcutaneous injection, currently being developed to improve glycemic control in patients with T2D. EXCEED 203 (NCT02057172), a 12-week study of EFPEG (0.3, 1, 2, 3, or

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b7401b2b4fc02c6259773dc88e62698e
https://doi.org/10.2337/db19-1014-p

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání